https://www.taxtmi.com/news?id=46207 The minister stated that Indian pharma firms do not copy foreign products and that no Swiss company produced evidence of infringement, emphasising India's opposition to ever-greening and citing Section 3(d) and Section 3(b) of the Patents Act as limits on patenting minor modifications. He also described cooperative engagement with Swiss and EFTA firms, improvements to IPR processes, reduced compliance burdens, faster approvals, and that no wrongdoing had been reported by companies. en-us Tue, 10 Jun 2025 20:31:05 +0530 Tue, 10 Jun 2025 20:31:05 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=46207 The minister stated that Indian pharma firms do not copy foreign products and that no Swiss company produced evidence of infringement, emphasising India's opposition to ever-greening and citing Section 3(d) and Section 3(b) of the Patents Act as limits on patenting minor modifications. He also described cooperative engagement with Swiss and EFTA firms, improvements to IPR processes, reduced compliance burdens, faster approvals, and that no wrongdoing had been reported by companies. News - Tue, 10 Jun 2025 20:31:05 +0530 https://www.taxtmi.com/news?id=46207